Provectus announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/688,319, Composition and Method for Treating Hematologic Cancers, covering the use of PV-10, a formulation of Provectus' immunogenic-small molecule and pharmaceutical-grade rose bengal sodium (RBS), for the treatment of hematologic diseases. In vivo data of mice with acute lymphoblastic leukemia receiving oral PV-10 showed increased survival compared to controls. This allowed patent application will be the first Provectus patent award in hematology from the USPTO.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1943 USD | 0.00% | +2.26% | +102.40% |
1st Jan change | Capi. | |
---|---|---|
+102.40% | 81.51M | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- PVCT Stock
- News Provectus Biopharmaceuticals, Inc.
- Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent Application for Use of PV-10® Immunotherapy in Hematology